CD36在非酒精性脂肪性肝病中的作用  

Role of CD36 in nonalcoholic fatty liver disease

作　　者：詹柱 任红[1] 彭明利[1] 

机构地区：[1]重庆医科大学附属第二医院感染科重庆医科大学病毒性肝炎研究所感染性疾病分子生物学教育部重点实验室,400010

出　　处：《中华肝脏病杂志》2017年第12期953-956,共4页Chinese Journal of Hepatology

摘　　要：非酒精性脂肪性肝病包括非酒精性单纯性脂肪肝、非酒精性脂肪性肝炎以及相关的肝硬化和肝癌，是目前全球最为常见的肝脏疾病，对其复杂的发病机制的探索是研究人员关注的重点。CD36是一种跨膜糖蛋白，因其在肝脏中主要发挥着脂肪酸摄取及结合氧化的低密度脂蛋白等作用，参与到了非酒精性脂肪性肝病的发生、发展过程。结合近期研究成果，现就CD36与非酒精性脂肪性肝病的关系及其发挥的作用进行综述。Nonalcoholic fatty liver disease （NAFLD） includes nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, liver cirrhosis, and liver cancer and is the most common liver disease in the world. The complex pathogenesis of NAFLD is a major concem among researchers. CD36 is a transmembrane glycopmtein that takes up fatty acid and binds to oxidized low-density lipoprotein in the liver, and therefore, it is involved in the development and progression of NAFLD. With reference to the latest research findings, this article reviews the association between CD36 and NAFLD and the role of CD36.

关 键 词：脂肪肝 非酒精性 脂肪酸类 CD36 

分 类 号：R575.5[医药卫生—消化系统]